releases: https://guest.house.gov/media/press-releases/congressman-guest-votes-against-hr-3
Data license: MIT · Data source: dwillis/congress-press
This data as json
| url | title | date | year | month | party | chamber | state | member_name | bioguide_id | domain | scraper | source | date_source | text | has_text | collected_at | updated_at |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| https://guest.house.gov/media/press-releases/congressman-guest-votes-against-hr-3 | Congressman Guest Votes Against H.R. 3 | 2019-12-12 | 2019 | 2019-12 | Republican | House | MS | Michael Guest | G000591 | guest.house.gov | guest | https://guest.house.gov/media/press-releases | scraper | Washington, DC – Today, Congressman Michael Guest (MS-03) voted against H.R. 3 – the Lower Drug Costs Now Act of 2019. Congressman Guest's primary concern was the likelihood that the bill would result in the creation of fewer cures and hinder the development of new drugs to treat illnesses. Recent reports indicate that over 100 cures could go undeveloped if Nancy Pelosi's bill were to become law. "There will be almost 2 million new cases of cancer in 2020. An estimated 5.8 million Americans suffer from Alzheimer's disease. Over 30 million U.S. adults are now living with diabetes. Just one new drug has the potential to change millions of lives. The loss of one potential new cure is unacceptable, but potentially killing over 100 new cures for the sake of a political agenda is unconscionable, especially when bipartisan, legislation exists that would lower drug costs without sacrificing new medicines. H.R. 19 – the Lower Costs, More Cures Act, has bipartisan support and would lower prescription drug prices without throwing away future cures that could change the lives of millions of Americans of all ages and walks of life." Congressman Guest is an original co-sponsor of H.R. 19 – the Lower Costs, More Cures Act. # # # | 1 | 2026-03-30T01:40:41Z | 2026-06-27T23:45:33Z |